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Introduction
Multiple Sclerosis (MS) is a chronic and a common inflammatory disorder of 
the central nervous system (CNS) characterized with myelin loss, progressive 
neurological dysfunction, gliosis, and unstable degrees of axonal pathology (1). 
Prevalence rates for MS vary between 2 and 2.5 million individuals worldwide(2).
While extensive investigation has been performed on the etiology and the 
pathogenesis of MS, up to now, no specific treatment, diagnostic test, or reliable 
biomarker has yet been recognized for MS patients(3).
Epidemiological studies in the relatives of affected individuals have shown that 
genetic risk factors are mainly responsible for a considerably increased frequency of 
the disease (4). Recently, other research suggests that disorders of the mitochondrial 
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Multiple Sclerosis (MS) is a common disease of the central nervous system. The 
interaction between inflammatory and neurodegenerative processes typically 
results in irregular neurological disturbances followed by progressive disability. 
Mitochondrial dysfunction has been implicated in neurodegenerative disorders. 
The DNA polymerase-gamma (POLG) gene, which encodes the catalytic 
subunit of enzyme responsible for directing mtDNA replication, contains a poly 
glutamine tract (poly-Q) in the N-terminal, encoded by a CAG sequence in exon 
2.
Materials & Methods
We analyzed the POLG trinucleotide repeats in 40 Iranian patients with MS (27 
females and 13 males with an age range of 18–55); and 47 healthy age, gender, 
and ethnic matched controls were chosen by PCR-SSCP analysis.
Results
Our results indicated that the most common allele in patients had 10 consecutive 
CAG repeats (10Q). Other alleles of 11and 12 trinucleotide repeats were detected. 
We did not find any difference between the CAG repeat length distribution in 
controls and MS patients.
Conclusion
No correlation was observed in the POLG gene CAG repeat with pathogenesis of 
MS, but it looks that other point mutations in POLG gene may have an important 
role in the disease’s pathogenesis and produced more significant results.
Keywords: Multiple sclerosis; POLG gene; CAG repeats; Trinucleotide 
expansion
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with idiopathic sporadic Parkinson’s(14), Friedreich 
ataxia(15), and Varicocele(16). The purpose of this 
study was to evaluate the association of POLG CAG 
repeat length with MS risk.
Materials & Methods
Patients
Relevant information was obtained from 40 patients 
with definite MS of all subtypes (Table 1). All study 
subjects gave informed consent. Further, 47 ethnically 
matched healthy unrelated individuals were enrolled 
into the study as the control group. All patients and the 
control group were informed of the aims of the study 
as well as gave informed consent for genetic analysis. 
Patients were diagnosed and referred for assessment by 
consultant neurologists from Yazd, Iran.
were present in patients with MS(5, 6). 
The only known mitochondrial DNA (mtDNA) 
polymerase is DNA polymerase γ (POLG) (7). The 
integrity of mtDNA is maintained by POLG(8). Its 
mature form contains of a polymerase domain with three 
polymerase motifs: A, B, and C; and an exonuclease 
domain. The POLG exonuclease domain consists of a 
CAG repeat region (encoded poly-Q) in exon 2, which 
is responsible for proofreading activity of the encoded 
enzymes(9). The length variation of the poly-Q may 
modulate enzyme function(10). Deletion analysis 
of the CAG repeat regions has shown that it may not 
effect enzymatic properties, but reasonably up-regulates 
the expression(11, 12). This CAG repeat explanation 
underlies various neurodegenerative disorders(13).
CAG Alternations have been found to be associated 
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Age 32.54 ± 8.51 36 ± 11.91 32± 8.7 50 ± 7.07
Age of onset (year) 28.61 ± 8.42 33.5 ± 12.26 30.3 ± 9.4 39.5 ± 0.7
 a: 18 female and13 male- b, c, d: female
DNA analysis
Genomic DNA was extracted from peripheral blood 
samples using a salting out technique. 286-bp DNA 
fragment were amplified by PCR in a volume of 25 μl, 
using two primers (GGTCCCTGCACCAACCATGA 
and CTTGCCCGAAGATTTGCTCGT); it has been 
published previously (17).
We used the SSCP technique for mutation analysis of 
the POLG gene. For the SSCP assay, PCR products 
were heat-denatured at 93ºC for 3 min and chilled on 
ice for 3 min, and loaded onto a polyacrylamide/TBE 
0.5x gel. After the run, the gel was removed from the 
apparatus and the DNA bands were visualized through 
silver staining. The SSCP variant bands on the gel were 
sent to be sequenced by an automated sequencing 3700 
ABI machine (Macrogene Seoul, South Korea). 
Statistical Method
The GraphPad Prism software was used for statistical 
analysis. The Fisher’s exact test was used to assess the 
association POLG CAG repeats in MS patients and 
the control group. P-values of <0.05 were considered 
statistically significant.
Results
Table 2 shows the allele and genotype frequencies 
of the CAG polymorphism in patients with MS and 
controls. In both patients and controls, there was a 
strong predominance of the allele 10Q. We did not find 
a statistically significant difference between the two 
studied groups. The frequency of the common POLG 
variant among the MS patients was 92.5%, which was 
similar to the control group (85.1%), (p=0.155). CAG 
repeat lengths ranging from 10–12 were detected, but 
not larger, expanded repeats were found in the control 
subjects and MS patients. 
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Discussion
DNA polymerase gamma is the only DNA polymerase 
active in the mitochondria. Interestingly, the human 
POLG gene includes a trinucleotide CAG repeat that 
is absent from the orthologue in other metazoans and 
yeast. The microsatellite repeat encodes a polyglutamine 
tract in the amino-terminal region of the POLG protein, 
downstream of the presumed mitochondrial targeting 
sequence(18).Mutations in the POLG gene have 
Fig 1. Genotyping of POLG CAG repeat by PCR-SSCP. 1, 4,
 and 5 are 10/≠10 genotype and 2, 3 are 10/10 genotype.
Table 2. POLG Exon 2 Poly Q (CAG-Repeat) Allele Frequencies.
Allele(number of CAG repeat) No. of alleles in patients No. of alleles in controls P–value Odd ratio
10 74(92.5%) 80 (85.1%) 0.155 2.15
11 5 (6.25%) 13 (13.82) 0.1349 0.415
12 1 (1.25%) 1 (1.06%) 1.000 1.17
Total 80 94 -
Genotype No. of patients No. of controls
10/10 homozygous 34 (85%) 33 (70.2%) 0.128 2.40
10/≠10 heterozygous 6 (15%) 14 (29.8%) 0.065 0.4160
40 47 -
a: Difference between MS and control group
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emerged as one of the most common causes of inherited 
mitochondrial disease in children and adults. They 
are responsible for a heterogeneous group of major 
phenotypes of neurodegenerative disease that include: 
childhood Myocerebrohepatopathy Spectrum disorders 
(MCHS) and Alpers-Huttenlocher syndrome, as well 
as mtDNA deletion disorders in the Ataxia Neuropathy 
Spectrum (ANS), which includes spinocerebellar ataxia 
with epilepsy (SCAE) and mitochondrial recessive 
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ataxia syndrome without ophthalmoplegia (MIRAS); 
Myoclonus Epilepsy Myopathy Sensory Ataxia 
(MEMSA); and autosomal dominant and recessive 
forms of progressive external ophthalmoplegia (PEO), 
which may include sensory ataxic neuropathy with 
dysarthria and ophthalmoparesis (SANDO), and 
cases of parkinsonism in PEO+ (19). Many studies 
show the involvement of the mitochondria in MS. 
First, ultrastructural analysis of demyelinated spinal 
cord lesions showed dramatically reduced numbers 
of mitochondria(5). Second, mitochondrial protein or 
DNA altered by mutation may trigger pathological 
immune response against self-epitopes potentially 
contributing to an autoimmune process(20). Third, a 
potential role for inherited mtDNA defects in MS is 
suggested by the tendency towards maternal inheritance, 
a hallmark of primary mitochondrial disorders, in a 
parent of origin half sibling study(21).Fourth, a number 
of MS cases bearing pathogenic mtDNA defects with 
Leber’s hereditary optic neuropathy (LHON) and MS 
(Harding’s disease) being the most well recognized, 
has been reported(22). Fifth, mutations in UCP2 (866 
G/A), ND2(5)and ATPase6(23)genes are reported to 
be implicated in patients with MS. Sixth, an energy 
deficient state has been implicated in the generation of 
axons the pathological correlate of disease progression 
in MS(24).The allele distribution of the poly-Q repeat 
of the POLG is relatively uniform in humans, as over 
80% of people in all studied populations carry the 10Q 
allele(11, 14, 15). Natural selection is a factor that could 
explain this, but is not clear at present whether purifying 
selection or low mutation rate is responsible for the 
unusually uniform allele distribution(10). Analysis CAG 
repeat length in Iranian MS patients samples did not 
show any detectable and no notable difference from that 
in the control subjects. The data presented in this study 
are inconsistent with the pathogenic role of the CAG 
polymorphism in MS.
Our previous findings on Friedreich’s ataxia patients 
showed a statistically significant inverse correlation 
between the POLG CAG repeats and age of onset in 
FRDA patients(15). Taanmana et al. has identified that 
the POLG CAG repeats are not a contributory factor in 
idiopathic Parkinson’s disease(18). These results warrant 
further study and more samples are needed to produce 
more significant results.
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